Prognostic biomarker in COVID-19 patients.
Patents for licensing
Never miss an update from María Mengual Mesa
Create your free account to connect with María Mengual Mesa and thousands of other innovative organizations and professionals worldwide
Technology Offer
Prognostic biomarker in COVID-19 patients.
- María from IBIMA-Plataforma Bionand
- From Spain
- Responsive
- Patents for licensing
Summary of the technology
Non-invasive method to predict the clinical deterioration of patients with COVID-19, based on the study of the mRNA expression of a gene.
The sample is taken from nasopharyngeal exudate, which offers two advantages: it is non-invasive, and it improves sensitivity (the primary impact of the virus occurs in the upper respiratory tract).
The method allows results to be obtained quickly and affordably by RT-PCR, a technique widely used in the health sector.
Results
Two cohorts of patients were used:
- Discovery cohort (149 patients): Panel analysis of genes related to inflammatory and immune response. A single gene was obtained with differential expression in patients who were discharged vs. admitted to ICU/exitus.
- Validation cohort (168 patients): Analysis revealed a significant association (p<0.05).
Medical Need
COVID-19 is a global health problem due to its high infection rate, the severity of the disease, the pressure on healthcare systems, its socioeconomic impact and the challenges in its control and prevention.
Having a prognostic marker for the evolution of patients with COVID-19 is critical to effectively manage the disease, allocate resources efficiently and improve patient outcomes.
Current development status
Laboratory prototypes
Desired business relationship
Technology selling
Patent licensing
Technology development
Intellectual property status
- Patent already applied for
- Patent application number :P202331044
Attached documents
Related Keywords
About IBIMA-Plataforma Bionand
IBIMA is a space for multidisciplinary research in biomedicine and nanomedicine that is centered around the Regional and Virgen de la Victoria University Hospitals in Malaga, together with Primary Care, the biotechnological groups of the University of Malaga and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND).
Send a request for information
to María
About Technology Offers
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Help
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
